Wells Fargo
ALZN icon

Wells Fargo’s Alzamend Neuro ALZN Stock Holding History

Wells Fargo’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-111
Closed -$1.69K – 7049
2024
Q3 		$1.69K Buy
+111
New +$2.9K ﹤0.01% 6071
2024
Q2 		– Hold
0
– -$39 – 6886
2024
Q1 		– Hold
0
– – – 6888
2023
Q4 		– Hold
0
– – – 7059
2023
Q3 		– Hold
0
– – – 6727
2023
Q2 		– Hold
0
– – – 6682
2023
Q1 		– Sell
-1
Closed -$752 – 6821
2022
Q4 		$785 Buy
+1
New +$1.45K ﹤0.01% 6261
2022
Q3 		– Hold
0
– – – 6611
2021
Q3 		– Hold
0
– -$2K – 6928
2021
Q2 		– Hold
0
– – – 6519

Other funds holding ALZN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo's ALZN Position: Q4 2024 in Review

Wells Fargo sold out of Alzamend Neuro (ALZN) in Q4 2024, closing a stake of 111 shares — an estimated $1.69K sold.

Wells Fargo first reported a position in ALZN in Q4 2022 and held it in 2 quarters. The position peaked at $1.69K in Q3 2024. 14 funds tracked by Wall St. Rank hold ALZN as of Q4 2024.

  • Wells Fargo reported no remaining Alzamend Neuro position as of Q4 2024 after selling out during the quarter.
  • Wells Fargo sold 111 Alzamend Neuro shares in Q4 2024, an estimated $1.69K.
  • Wells Fargo first reported a position in Alzamend Neuro in Q4 2022 and held it in 2 quarters.
  • Wells Fargo's Alzamend Neuro position peaked at $1.69K in Q3 2024.
  • 14 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2024.

Based on Wells Fargo's 13F filing for Q4 2024, filed 13 Feb 2025.